What were the price details of the share sales?

One sale used a weighted average price of $27.22 , with individual trades ranging from $27.00 to $27.38 ; another sale was at $27.30 .

QURE insider trades: option exercise and subsequent share sales reported

Q: What did QURE’s director report on Form 4?

An option exercise for 15,840 shares at $4.57 and two sales: 15,840 shares at a weighted average $27.22 and 15,594 shares at $27.30 .

Q: How many QURE shares does the reporting person own after the trades?

The filing shows 40,145 shares beneficially owned directly after the reported transactions.

Q: Was a Rule 10b5-1 trading plan used for these transactions?

Yes. The transactions were made under a Rule 10b5-1 plan adopted on July 8, 2025 .

Q: What are the key terms of the exercised option?

It covered 15,840 shares at an exercise price of $4.57 , vested in full on June 19, 2025 , and expires on 06/19/2034 .

Q: What is the insider’s relationship to uniQure (QURE)?

The reporting person is a Director of uniQure N.V.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

uniQure N.V. (QURE) disclosed insider transactions by a director on a Form 4 dated 11/06/2025. The reporting person exercised stock options for 15,840 ordinary shares at an exercise price of $4.57 (code M), then reported two open-market sales (code S): 15,840 shares at a weighted average price of $27.22 and 15,594 shares at $27.30. Following these transactions, 40,145 shares were beneficially owned directly.

The transactions were effected under a Rule 10b5-1 plan adopted on July 8, 2025. The filing notes footnote adjustments to prior reported holdings, and states the first sale’s weighted average reflects multiple trades between $27.00 and $27.38. The option covered 15,840 underlying shares, vested in full on June 19, 2025, and carries an expiration date of 06/19/2034.

Insider Trade Summary

Net Seller: 31,434 shares ($856,881)

Net Sell 4 txns

Insider Gut Robert

Role Director

Sold 31,434 shs ($857K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,840	$0.00	--
Exercise	Ordinary Shares	15,840	$4.57	$72K
Sale	Ordinary Shares	15,840	$27.22	$431K
Sale	Ordinary Shares	15,594	$27.30	$426K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Ordinary Shares — 71,579 shares (Direct)

Footnotes (1)

The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Adjusted to reflect (i) the sale of 1,120 shares under the Reporting Person's 10b5-1 plan on June 23, 2020, which was inadvertently omitted from the Form 4 filed on June 24, 2020, and (ii) the correction to a typographical error in the number of shares sold by the Reporting Person on June 13, 2024 reported on the Form 4 filed on June 17, 2024. The Form 4 reported the sale of 3,504 shares but should have reported the sale of 3,524 shares. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.00 to $27.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested in full on June 19, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/10/2025 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gut Robert

(Last)

(First)

(Middle)

C/O UNIQURE N.V.

PAASHEUVELWEG 25A

(Street)

AMSTERDAM

11058BP

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/06/2025		M⁽¹⁾		15,840	A	$4.57	71,579⁽²⁾	D
Ordinary Shares	11/06/2025		S⁽¹⁾		15,840	D	$27.22⁽³⁾	55,739	D
Ordinary Shares	11/06/2025		S⁽¹⁾		15,594	D	$27.3	40,145	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.57	11/06/2025		M⁽¹⁾			15,840	⁽⁴⁾	06/19/2034	Ordinary Shares	15,840	$0	0	D

Explanation of Responses:

1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

2. Adjusted to reflect (i) the sale of 1,120 shares under the Reporting Person's 10b5-1 plan on June 23, 2020, which was inadvertently omitted from the Form 4 filed on June 24, 2020, and (ii) the correction to a typographical error in the number of shares sold by the Reporting Person on June 13, 2024 reported on the Form 4 filed on June 17, 2024. The Form 4 reported the sale of 3,504 shares but should have reported the sale of 3,524 shares.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.00 to $27.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The Stock Option vested in full on June 19, 2025.

	/s/ Christian Klemt, Attorney-in-Fact	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did QURE’s director report on Form 4?

An option exercise for 15,840 shares at $4.57 and two sales: 15,840 shares at a weighted average $27.22 and 15,594 shares at $27.30.

How many QURE shares does the reporting person own after the trades?

The filing shows 40,145 shares beneficially owned directly after the reported transactions.

Was a Rule 10b5-1 trading plan used for these transactions?

Yes. The transactions were made under a Rule 10b5-1 plan adopted on July 8, 2025.

What are the key terms of the exercised option?

It covered 15,840 shares at an exercise price of $4.57, vested in full on June 19, 2025, and expires on 06/19/2034.

What is the insider’s relationship to uniQure (QURE)?

The reporting person is a Director of uniQure N.V.